Dose linearity study of selegiline pharmacokinetics after oral administration: Evidence for strong drug interaction with female sex steroids

British Journal of Clinical Pharmacology

Volumn 47, Issue 3, 1999, Pages 249-254

  Laine, Kari ^a   Anttila, Markku ^b   Helminen, Antti ^a   Karnani, Hari ^b   Huupponen, Risto ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b ORION CORPORATION   (Finland)

Author keywords

Desmethylselegiline; Female sex steroids; Interaction; Pharmacokinetics; Selegiline

Indexed keywords

MONOAMINE OXIDASE INHIBITOR; ORAL CONTRACEPTIVE AGENT; SELEGILINE; SEX HORMONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; GAS CHROMATOGRAPHY; HUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AMPHETAMINES; ANTIPARKINSON AGENTS; AREA UNDER CURVE; CONTRACEPTIVE AGENTS, FEMALE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; SELEGILINE;

EID: 0033037958     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00891.x     Document Type: Article

References (23)

1. 1 Koller WC. Selegiline monotherapy in the treatment of Parkinson's disease. Neurology 1996; 47: S196-S199.
2. 2 The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328: 176-183.
3. 3 Myllylä VV, Sotaniemi K, Mäki-Ikola O, Rinne UK, Heinonen EH. Role of sclegiline in combination therapy of Parkinson's disease. Neurology 1996; 47: S200-S209.
4. 4 Knoll J. The possible mechanism of action of (-) -deprenyl in Parkinson's disease. J Neural Transm 1978; 43: 177-198.
5. 5 Borbe HO, Niebch G, Nickel B. Kinetic evaluation of MAO-B-activity following oral administration of selegiline and desmethylselegiline in rat. J Neural Transm 1990; 32: 131-137.
6. 6 Heinonen EH, Anttila MI, Nyman L, et al. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of MAO-B in human subjects. J Clin Pharmacol 1997; 37: 602-609.
7. 7 Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side-effects of 1-deprenyl. Arch Gen Psychiatry 1989; 46: 45-50.
8. 8 Sunderland T, Cohen R, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994; 51: 607-615.
9. 9 Hublin C, Partinen M, Heinonen EH, Puukka P, Salmi T. Selegiline in the treatment of narcolepsy. Neurology 1994; 44: 2095-2101.
10. 10 Heinonen EH, Anttila M, Karnani H, Lammintausta R. Pharmacokinetics of selegiline after oral dosing. Mov Disord 1994; 9(Suppl 1): P248.
11. 11 Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 1997; 33: 91-102.
12. 12 Schultz R, Antonin K-H, Hoffman E, et al. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 1989; 46: 528-536.
13. 13 Karnani H, Anttila M. Determination of selegiline and desmethylselegiline in human serum by gas-chromatography using nitrogen selective detection. Bioanalytical method report, data on file Orion Pharma 1993.
14. 14 Heinonen EH, Anttila MI, Lammintausta RAS. Pharmacokinetic aspects of 1-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther 1994; 56: 742-749.
15. 15 Wacher VJ, Wong S, Wong HT, Benet LZ. Contribution of CYP3A to selegiline metabolism in rat and human liver microsomcs. ISSX Proceedings 1996; 10: 351.
16. 16 Pazzucconi F, Malavasi B, Galli G, Franceschini G, Calabresi L, Sirtori CR. Inhibition of antipyrine metabolism by low-dose contraceptives with gestodene and desogestrel. Clin Pharmacol Ther 1991; 49: 278-284.
17. 17 Balogh A, Klinger G, Henschel L, Borner A, Vollanth R, Kuhnz W. Influence of ethinylestradiol containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol 1995; 48: 161-166.
18. 18 Knights KM, McLean CE, Tonkin AL, Miners JO. Lack of effect of gender and oral contraceptive steroids on the pharmacokinetics of (R) -ibuprofen in humans. Br J Clin Pharmacol 1995; 40: 153-156.
19. 19 Slayter KL, Ludwig EA, Lew KH, Middleton E, Jr, Ferry JJ, Jusko WJ. Oral contraceptive effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1996; 59: 312-321.
20. 20 Guengerich FP. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem Res Toxicol 1990; 3: 363-371.
21. 21 Böcker R, Kleingeist B, Eichhorn M, et al. In vitro interaction of contraceptive steroids with human liver cytochrome P-450 enzymes. Adv Contracept 1991; 7(Suppl 3): 140-148.
22. 22 Relling MV. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 1996; 18: 350-356.
23. 23 Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 1963; ii: 849-851.